Clinical Trial Update: Safety and Efficacy Study With Catumaxomab in Patients After Curative Resection of a Gastric Adenocarcinoma [Phase 2]

View source ↗

Summary

Phase 2 study evaluating the safety and efficacy of Catumaxomab in patients after curative resection of gastric adenocarcinoma has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Gastric Adenocarcinoma

Drugs mentioned

• Catumaxomab (Catumaxomab)

Snippet

Sponsor: Neovii Biotech | Conditions: Gastric Cancer, Gastric Adenocarcinoma | Phase 2 | Status: COMPLETED